Loading...

Biosimilars in Osteoporosis: Real-World Evidence

Meeting Room

Friday, September 27, 2024

Luncheon CME Satellite Symposium at the ASBMR, Metro Toronto Convention Centre

255 Front Street West

Toronto, Ontario, Canada

You must be registered for the ASBMR annual meeting to attend this presentation.

Biosimilars are large, complex molecules made from living organisms that are highly similar to their reference biologic and are administered in the same way, with the same strength and dosage, and clinically meaningful differences in safety, purity, and potency. Endocrinologists are challenged to stay apprised of the latest developments and emerging science in this evolving therapeutic space.

In this live CME-accredited satellite symposium, our key opinion leaders will discuss how biosimilars are regularly used in the treatment of other disorders. Using real-world evidence, a review of the latest clinical trial data using biosimilars for treating osteoporosis will be presented. Biosimilar therapies offer an alternative treatment option that may be safely integrated into clinical practice to deliver high quality care and positive effects on bone health.

Schedule

* Times are EST
12:25 PM Luncheon
12:30 PM Welcome, Disclosures, Supporter Acknowledgement
12:35 PM Biosimilars: Patient Cases

Aliya Khan, MD, FRCPC

Clinical Professor of Medicine
Divisions of Endocrinology and Geriatrics
Director, Calcium Disorders Clinic
Director, Fellowship in Metabolic Bone Disease
McMaster University
Hamilton, ON, Canada

01:00 PM Clinical Trial Data

Alan J. Kivitz, MD, MACR

Medical Director
Altoona Arthritis and Osteoporosis Center
Altoona Center for Clinical Research
Duncansville, PA, USA

01:20 PM Audience Q&A
01:30 PM Adjourn

Accreditation

EXCEL Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

EXCEL Continuing Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Canadian CME: Through an agreement between the ACCME and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

The UEMS-EACCME®: European Union of Medical Specialists and European Accreditation Council for CME have mutual recognition agreements with the American Medical Association for live events and e-learning materials. European physicians can earn their ECMEC®s (European CME credits) by either attending a live presentation approved by an ACCME accredited provider such as EXCEL or participating in e-learning activities (on-demand webcasts) from accredited providers from the USA that have been certified for AMA PRA Category 1 Credits™.

Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits TM through their reciprocity agreements.

Educational Objectives

At the conclusion of this conference, you should be able to:
  • Define biosimilars and how these new agents can help close the treatment gap for managing individuals with osteoporosis and at increased risk of fractures
  • Using patient cases from other disorders, explain how biosimilars have resulted in positive patient outcomes
  • Review clinical trial data for biosimilar agents being investigated for the treatment of osteoporosis

Supporter

SANDOZ